We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UPXI:NASDAQUpexi, Inc. Analysis

Data as of 2026-07-15 - not real-time

$0.84

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Upexi, Inc. (UPXI) is trading well below its short‑ and long‑term moving averages – the price of $0.84 sits under the 20‑day SMA (≈$0.85), the 50‑day SMA (≈$1.08) and the 200‑day SMA (≈$2.12), confirming a bearish technical backdrop. The RSI of 44.8 suggests the stock is not yet oversold, while the MACD shows a modest bullish histogram (+0.011) but the overall trend remains down‑trend with decreasing volume. Volatility is extreme at over 106% 30‑day, and a beta of ~4.5 indicates the stock moves dramatically more than the market, amplifying risk.
Fundamentally, the company is distressed: operating margins are –23%, EBITDA is heavily negative, cash flow is negative, and debt exceeds $242 million against a meager cash balance of $3.5 million. The price‑to‑earnings ratio of 1.44 looks cheap only because earnings are marginal, and the price‑to‑book is negative (‑1.08). No dividend is paid, and ROA is –1.27%. The recent inclusion in the Russell Microcap® Index may boost visibility, and the firm’s focus on a Solana‑based digital‑asset treasury adds crypto‑related regulatory uncertainty. Overall, the technical weakness, extreme volatility, and weak fundamentals outweigh the modest valuation allure.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Price below all major SMAs indicating bearish momentum
  • Decreasing volume and extreme 30‑day volatility
  • Negative operating cash flow and high debt load

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential institutional inflow from Russell Microcap index inclusion
  • Crypto‑treasury exposure could improve if market sentiment shifts
  • Continued earnings weakness and cash burn

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Sustained negative profitability and deteriorating balance sheet
  • High beta and volatility make risk‑adjusted returns unattractive
  • Regulatory uncertainty surrounding digital‑asset activities

Key Metrics & Analysis

Financial Health

Revenue Growth44.20%
P/E Ratio1.4
ROA-126.53%
P/B Ratio-1.1
Op. Cash Flow$-21524226
Free Cash Flow$-229092160
Industry P/E16.2

Technical Analysis

TrendBearish
RSI44.8
Support$0.74
Resistance$1.12
MA 20$0.85
MA 50$1.08
MA 200$2.12
MACDBullish
VolumeDecreasing
Fear & Greed Index91.96

Valuation

Target Price$1.30
Upside/Downside55.28%
GradeOvervalued
TypeValue

Risk Assessment

Beta4.53
Volatility106.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.